Do analysts rate BPTSY or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BPTSY or PPCB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is BPTSY or PPCB more profitable?

Biophytis' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Propanc Biopharma N/A -151.28% -109.53%

Which has stronger earnings & valuation, BPTSY or BPTH?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is BPTSY or BPTH more profitable?

Biophytis' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend BPTSY or CANF?

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,296.83%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, BPTSY or CANF?

Can-Fite BioPharma has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Can-Fite BioPharma $405K 5.09 -$7.63M -$22.80 N/A

Is BPTSY or CANF more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Can-Fite BioPharma N/A N/A N/A

Which has better earnings & valuation, ORGS or BPTSY?

Biophytis has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 5.54 -$55.36M -$11.51 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ORGS or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Biophytis N/A N/A N/A

Do analysts recommend BPTSY or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BPTSY or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A China SXT Pharmaceuticals $1.14M 2.07 -$6.20M N/A N/A

Is BPTSY or SXTC more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A China SXT Pharmaceuticals N/A N/A N/A

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 07/31/2026

Compare

BPTSY vs. PPCB, BPTH, CANF, ORGS, and SXTC

Should you buy Biophytis stock or one of its competitors? MarketBeat compares Biophytis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biophytis include Propanc Biopharma (PPCB), Bio-Path (BPTH), Can-Fite BioPharma (CANF), Orgenesis (ORGS), and China SXT Pharmaceuticals (SXTC).

How does Biophytis compare to Propanc Biopharma?

Biophytis (NASDAQ:BPTSY) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Propanc Biopharma's average media sentiment score of 0.44 beat Biophytis' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
Propanc Biopharma	Neutral

0.1% of Biophytis shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biophytis' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Propanc Biopharma	N/A	-151.28%	-109.53%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, suggesting that its share price is 249% more volatile than the broader market.

Summary

Biophytis and Propanc Biopharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Biophytis compare to Bio-Path?

Biophytis (NASDAQ:BPTSY) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Biophytis' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

0.1% of Biophytis shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Bio-Path	Neutral

Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, meaning that its share price is 151% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

Biophytis beats Bio-Path on 4 of the 6 factors compared between the two stocks.

How does Biophytis compare to Can-Fite BioPharma?

Biophytis (NASDAQ:BPTSY) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,296.83%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Can-Fite BioPharma	Neutral

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Can-Fite BioPharma	$405K	5.09	-$7.63M	-$22.80	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Can-Fite BioPharma	N/A	N/A	N/A

Summary

Can-Fite BioPharma beats Biophytis on 6 of the 8 factors compared between the two stocks.

How does Biophytis compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Orgenesis had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Orgenesis and 0 mentions for Biophytis. Orgenesis' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Biophytis	Neutral

Orgenesis has a beta of 3.14, indicating that its share price is 214% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Biophytis	N/A	N/A	N/A

Biophytis has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	5.54	-$55.36M	-$11.51	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Summary

Orgenesis and Biophytis tied by winning 4 of the 8 factors compared between the two stocks.

How does Biophytis compare to China SXT Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
China SXT Pharmaceuticals	N/A	N/A	N/A

In the previous week, China SXT Pharmaceuticals' average media sentiment score of 1.01 beat Biophytis' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
China SXT Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China SXT Pharmaceuticals has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
China SXT Pharmaceuticals	$1.14M	2.07	-$6.20M	N/A	N/A

Summary

China SXT Pharmaceuticals beats Biophytis on 6 of the 7 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$586K	$12.89B	$7.24B	$12.30B
Dividend Yield	N/A	2.72%	2.59%	9.45%
P/E Ratio	N/A	793.97	280.89	24.66
Price / Sales	N/A	938.31	641.00	110.52
Price / Cash	N/A	76.57	71.02	59.62
Price / Book	-0.02	10.92	11.09	5.90
Net Income	-$18.43M	$2.82B	$3.50B	$336.31M
7 Day Performance	N/A	-0.21%	-0.25%	0.09%
1 Month Performance	N/A	-3.31%	-2.98%	-5.67%
1 Year Performance	N/A	155.31%	61.96%	18.79%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
PPCB Propanc Biopharma	0.3627 of 5 stars	$0.98 -18.9%	N/A	-99.6%	$2.24M	N/A	N/A	1	Analyst Forecast
BPTH Bio-Path	N/A	$0.04 flat	N/A	-74.7%	$2.21M	N/A	N/A	10	Gap Up
CANF Can-Fite BioPharma	1.6592 of 5 stars	$3.25 +2.7%	$44.00 +1,255.9%	-76.5%	$2.13M	$405K	N/A	8
ORGS Orgenesis	N/A	$0.40 flat	N/A	+3,127.3%	$2.07M	$662K	N/A	150	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. PPCB, BPTH, CANF, ORGS, and SXTC

How does Biophytis compare to Propanc Biopharma?

Summary

How does Biophytis compare to Bio-Path?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Summary

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to China SXT Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. PPCB, BPTH, CANF, ORGS, and SXTC

How does Biophytis compare to Propanc Biopharma?

Does the media refer more to BPTSY or PPCB?

Do institutionals and insiders have more ownership in BPTSY or PPCB?

Is BPTSY or PPCB more profitable?

Which has higher valuation and earnings, BPTSY or PPCB?

Do analysts rate BPTSY or PPCB?

Which has more risk & volatility, BPTSY or PPCB?

Summary

How does Biophytis compare to Bio-Path?

Is BPTSY or BPTH more profitable?

Do institutionals and insiders have more ownership in BPTSY or BPTH?

Does the media favor BPTSY or BPTH?

Which has more volatility & risk, BPTSY or BPTH?

Which has stronger earnings & valuation, BPTSY or BPTH?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Which has more volatility and risk, BPTSY or CANF?

Do analysts recommend BPTSY or CANF?

Do insiders & institutionals believe in BPTSY or CANF?

Does the media favor BPTSY or CANF?

Which has higher valuation & earnings, BPTSY or CANF?

Is BPTSY or CANF more profitable?

Summary

How does Biophytis compare to Orgenesis?

Does the media prefer ORGS or BPTSY?

Which has more volatility and risk, ORGS or BPTSY?

Do institutionals & insiders hold more shares of ORGS or BPTSY?

Is ORGS or BPTSY more profitable?

Which has better earnings & valuation, ORGS or BPTSY?

Summary

How does Biophytis compare to China SXT Pharmaceuticals?

Do insiders and institutionals hold more shares of BPTSY or SXTC?

Which has more risk & volatility, BPTSY or SXTC?

Is BPTSY or SXTC more profitable?

Does the media refer more to BPTSY or SXTC?

Do analysts recommend BPTSY or SXTC?

Which has higher valuation and earnings, BPTSY or SXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools